Performance of novel non-invasive urine assay UroSEEK in cohorts of equivocal urine cytology

[1]  K. Kinzler,et al.  Targeted sequencing of plasmacytoid urothelial carcinoma reveals frequent TERT promoter mutations. , 2019, Human pathology.

[2]  A. Jemal,et al.  Cancer statistics, 2019 , 2019, CA: a cancer journal for clinicians.

[3]  Ludmila V. Danilova,et al.  Non-invasive detection of urothelial cancer through the analysis of driver gene mutations and aneuploidy , 2018, eLife.

[4]  X. Ju,et al.  Evaluation of the NMP22 BladderChek test for detecting bladder cancer: a systematic review and meta-analysis , 2017, OncoTarget.

[5]  K. Kinzler,et al.  Spectrum of genetic mutations in de novo PUNLMP of the urinary bladder , 2017, Virchows Archiv.

[6]  S. Pambuccian,et al.  The value of the UroVysion® FISH assay in the risk‐stratification of patients with “atypical urothelial cells” in urinary cytology specimens , 2017, Diagnostic cytopathology.

[7]  K. Kinzler,et al.  High prevalence of TERT promoter mutations in micropapillary urothelial carcinoma , 2016, Virchows Archiv.

[8]  K. Kinzler,et al.  Detection of TERT promoter mutations in primary adenocarcinoma of the urinary bladder. , 2016, Human pathology.

[9]  M. Quek,et al.  The Paris System for Reporting Urinary Cytology: The Quest to Develop a Standardized Terminology. , 2016, Advances in anatomic pathology.

[10]  Yu Zhang,et al.  Diagnostic Value of Urine Cytology in Bladder Cancer. A Meta-Analysis. , 2016, Analytical and quantitative cytopathology and histopathology.

[11]  D. Dietrich,et al.  Epigenetic biomarkers in the blood of patients with urological malignancies , 2015, Expert review of molecular diagnostics.

[12]  F. Brimo,et al.  Prospective analysis of sensitivity and specificity of urinary cytology and other urinary biomarkers for bladder cancer. , 2015, Urologic oncology.

[13]  Navneeta Bansal,et al.  Low- and high-grade bladder cancer appraisal via serum-based proteomics approach. , 2014, Clinica chimica acta; international journal of clinical chemistry.

[14]  G. Kristiansen,et al.  Nucleic acid-based biomarkers in body fluids of patients with urologic malignancies , 2014, Critical reviews in clinical laboratory sciences.

[15]  P. Rothberg,et al.  Mutations of the TERT promoter are common in basal cell carcinoma and squamous cell carcinoma , 2014, Modern Pathology.

[16]  K. Hemminki,et al.  TERT promoter mutations in cancer development. , 2014, Current opinion in genetics & development.

[17]  M. Knowles,et al.  Comprehensive mutation analysis of the TERT promoter in bladder cancer and detection of mutations in voided urine. , 2014, European urology.

[18]  F. Mege-Lechevallier,et al.  Diagnostic terminology for urinary cytology reports including the new subcategories ‘atypical urothelial cells of undetermined significance’ (AUC‐US) and ‘cannot exclude high grade’ (AUC‐H) , 2014, Cytopathology : official journal of the British Society for Clinical Cytology.

[19]  T. Ørntoft,et al.  Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome. , 2014, European urology.

[20]  K. Kinzler,et al.  TERT promoter mutations occur early in urothelial neoplasia and are biomarkers of early disease and disease recurrence in urine. , 2013, Cancer research.

[21]  Gary L. Gallia,et al.  TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal , 2013, Proceedings of the National Academy of Sciences.

[22]  C. VandenBussche,et al.  The Johns Hopkins Hospital template for urologic cytology samples , 2013, Cancer cytopathology.

[23]  C. VandenBussche,et al.  The Johns Hopkins Hospital template for urologic cytology samples , 2013, Cancer cytopathology.

[24]  K. Kinzler,et al.  FAST-SeqS: A Simple and Efficient Method for the Detection of Aneuploidy by Massively Parallel Sequencing , 2012, PloS one.

[25]  G. Netto.  Molecular biomarkers in urothelial carcinoma of the bladder: are we there yet? , 2012, Nature Reviews Urology.

[26]  P. Guldberg,et al.  Integrated genetic and epigenetic analysis of bladder cancer reveals an additive diagnostic value of FGFR3 mutations and hypermethylation events , 2011, International journal of cancer.

[27]  K. Kinzler,et al.  Detection and quantification of rare mutations with massively parallel sequencing , 2011, Proceedings of the National Academy of Sciences.

[28]  Nilay,et al.  The diagnostic value of the urine cytology in bladder cancer , 2011 .

[29]  T. H. van der Kwast,et al.  FGFR3, HRAS, KRAS, NRAS and PIK3CA Mutations in Bladder Cancer and Their Potential as Biomarkers for Surveillance and Therapy , 2010, PloS one.

[30]  J. Rao,et al.  Urine cytology and adjunct markers for detection and surveillance of bladder cancer. , 2010, American journal of translational research.

[31]  T. Furuya,et al.  9p21 index as estimated by dual-color fluorescence in situ hybridization is useful to predict urothelial carcinoma recurrence in bladder washing cytology. , 2009, Human pathology.

[32]  K. Halling,et al.  Bladder Cancer Detection Using FISH (UroVysion Assay) , 2008, Advances in anatomic pathology.

[33]  Ram H Datar,et al.  Molecular pathways in invasive bladder cancer: new insights into mechanisms, progression, and target identification. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  N. Malats,et al.  PIK3CA mutations are an early genetic alteration associated with FGFR3 mutations in superficial papillary bladder tumors. , 2006, Cancer research.

[35]  S. Johansson,et al.  Use of a multitarget fluorescence in situ hybridization assay to diagnose bladder cancer in patients with hematuria. , 2006, The Journal of urology.

[36]  Xue-Ru Wu.  Urothelial tumorigenesis: a tale of divergent pathways , 2005, Nature Reviews Cancer.

[37]  D. Theodorescu,et al.  The role of Ras superfamily proteins in bladder cancer progression. , 2003, The Journal of urology.

[38]  A. Feller,et al.  Numerical aberrations of chromosome 17 and the 9p21 locus are independent predictors of tumor recurrence in non-invasive transitional cell carcinoma of the urinary bladder. , 2003, International journal of oncology.

[39]  J. Jones,et al.  Multitarget fluorescence in situ hybridization assay detects transitional cell carcinoma in the majority of patients with bladder cancer and atypical or negative urine cytology. , 2003, The Journal of urology.

[40]  C. Roehrborn,et al.  Sensitivity and specificity of commonly available bladder tumor markers versus cytology: results of a comprehensive literature review and meta-analyses. , 2003, Urology.

[41]  Y. Fradet,et al.  Performance characteristics of a new monoclonal antibody test for bladder cancer: ImmunoCyt trade mark. , 1997, The Canadian journal of urology.

[42]  Jeffrey K. Cohen,et al.  Origins and clinical implications of aneuploidy in early bladder cancer. , 1995, Cytometry.

[43]  C. Cordon-Cardo,et al.  Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression. , 1993, Journal of the National Cancer Institute.

[44]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.